{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:11:19Z","timestamp":1775754679274,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.08.084","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T07:39:30Z","timestamp":1693553970000},"page":"6215-6220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12\u00a0months to 49\u00a0years of age: A phase II\/III, randomized, single blind, non-inferiority study"],"prefix":"10.1016","volume":"41","author":[{"given":"Sai Krishna","family":"Susarla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kheya Ghosh","family":"Uttam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonali","family":"Palkar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish Ramachandra","family":"Dhongade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Siva Ram Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasudev","family":"Rajapantula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.D.","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Satish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.C.","family":"Rajashakar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Sandhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2881-8464","authenticated-orcid":false,"given":"L.","family":"Rajendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devi Prasad","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand Kumar","family":"Kanakasapapathy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.084_b0005","unstructured":"WHO Fact sheets Hepatitis A. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-a [accessed on 30th November 2022]."},{"key":"10.1016\/j.vaccine.2023.08.084_b0010","unstructured":"WHO position paper on hepatitis A vaccines-October 2022. Weekly Epidemiological Record; 7 October 2022 [accessed on 30th November 2022]."},{"key":"10.1016\/j.vaccine.2023.08.084_b0015","unstructured":"Global Health Metrics. Acute hepatitis A-level 4 cause. https:\/\/www.healthdata.org\/results\/gbd_summaries\/2019\/acute-hepatitis-a-level-4-cause [accessed on 30th November 2022]."},{"issue":"8","key":"10.1016\/j.vaccine.2023.08.084_b0020","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.4161\/hv.20475","article-title":"Hepatitis A vaccine should receive priority in National Immunization Schedule in India","volume":"8","author":"Verma","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2023.08.084_b0025","unstructured":"CDC Viral Hepatitis Surveillance \u2014 India, 2011\u20132013. Morbidity and Mortality Weekly Report (MMWR); July 24, 2015. https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm6428a3.htm [accessed on 30th November 2022]."},{"issue":"13","key":"10.1016\/j.vaccine.2023.08.084_b0030","first-page":"2022","article-title":"Epidemiology, high-risk groups, prevention and research on antiviral treatment","volume":"2021","author":"Hepatitis","year":"1900","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.08.084_b0035","unstructured":"Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices; 2020. https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/rr\/rr6905a1.htm [accessed on 30th November 2022]."},{"key":"10.1016\/j.vaccine.2023.08.084_b0040","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) - Version 5.0; Published; November 27, 2017. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute."},{"key":"10.1016\/j.vaccine.2023.08.084_b0045","unstructured":"Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 July 2017. Division of AIDS, National Institute of Allergy and Infectious Diseases. National Institutes of Health. US Department of Health and Human Services. https:\/\/rsc.niaid.nih.gov\/clinical-research-sites\/daids-adverse-event-grading-tables [accessed on 30th November 2022]."},{"issue":"811","key":"10.1016\/j.vaccine.2023.08.084_b0050","article-title":"Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: results from a randomized, parallel controlled, phase IV study","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2023.08.084_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3346\/jkms.2016.31.1.73","article-title":"Reappraisal of the immunogenicity and safety of three hepatitis A vaccines in adolescents","volume":"31","author":"Yoon","year":"2016","journal-title":"Korean Med Sci"},{"issue":"7","key":"10.1016\/j.vaccine.2023.08.084_b0060","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/21645515.2015.1045167","article-title":"A retrospective pooled analysis assessing the effect of age on the immunogenicity of Havrix\u2122 in healthy adults","volume":"11","author":"Meeren","year":"2015","journal-title":"Hum Vacc Immunotherapeut"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.084_b0065","article-title":"Immunogenicity and safety of a new inactivated Hepatitis A vaccine in Thai young adults","volume":"29","author":"Poovorawan","year":"1998","journal-title":"Southeast Asian J Trop Med Public Health"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:30:13Z","timestamp":1759404613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23010502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":13,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X23010502"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12\u00a0months to 49\u00a0years of age: A phase II\/III, randomized, single blind, non-inferiority study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}